The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.

Multiple sclerosis (MS), is a chronic disease of the central nervous system (CNS) characterized by loss of motor and sensory function, that results from immune-mediated inflammation, demyelination and subsequent axonal damage. MS is one of the most common causes of neurological disability in young adults. Several variants of MS (and CNS demyelinating syndromes in general) have been nowadays defined in an effort to increase the diagnostic accuracy, to identify the unique immunopathogenic profile and to tailor treatment in each individual patient. These include the initial events of demyelination defined as clinically or radiologically isolated syndromes (CIS and RIS respectively), acute disseminated encephalomyelitis (ADEM) and its variants (acute hemorrhagic leukoencephalitis-AHL, Marburg variant, and Balo's concentric sclerosis), Schilder's sclerosis, transverse myelitis, neuromyelitis optica (NMO and NMO spectrum of diseases), recurrent isolated optic neuritis and tumefactive demyelination. The differentiation between them is not only a terminological matter but has important implications on their management. For instance, certain patients with MS and prominent immunopathogenetic involvement of B cells and autoantibodies, or with the neuromyelitic variants of demyelination, may not only not respond well but even deteriorate under some of the first-line treatments for MS. The unique clinical and neuroradiological features, along with the immunological biomarkers help to distinguish these cases from classical MS. The use of such immunological and imaging biomarkers, will not only improve the accuracy of diagnosis but also contribute to the identification of the patients with CIS or RIS who, are at greater risk for disability progression (worse prognosis) or, on the contrary, will have a more benign course. This review summarizes in a critical way, the diagnostic criteria (historical and updated) and the definitions/characteristics of MS of the various variants/subtypes of CNS demyelinating syndromes.

[1]  L. Kappos,et al.  Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis , 2004, Neuroradiology.

[2]  S. L. Galetta,et al.  The utility of MRI in suspected MS , 2003, Neurology.

[3]  M. Tardieu,et al.  What is acute disseminated encephalomyelitis (ADEM)? , 2004, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[4]  V. Brinar,et al.  Diagnostic imaging in acute disseminated encephalomyelitis , 2010, Expert review of neurotherapeutics.

[5]  J. L. Cox,et al.  Neuroimaging in multiple sclerosis. , 2007, International review of neurobiology.

[6]  V. Tomassini,et al.  Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS , 2007, Multiple sclerosis.

[7]  P. Narayana,et al.  Improved Identification of Intracortical Lesions in Multiple Sclerosis with Phase-Sensitive Inversion Recovery in Combination with Fast Double Inversion Recovery MR Imaging , 2007, American Journal of Neuroradiology.

[8]  H. Mattle,et al.  Anti‐myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort , 2007, Acta neurologica Scandinavica.

[9]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[10]  J. Bennett,et al.  The B cell response in multiple sclerosis , 2006, Neurological research.

[11]  À. Rovira,et al.  Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report. , 2002, AJNR. American journal of neuroradiology.

[12]  H. Tumani,et al.  Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases , 2009, Journal of Neuroimmunology.

[13]  A. Thompson,et al.  C onversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fl uid and neurophysiological findings , 2003, Multiple sclerosis.

[14]  H. Ulmer,et al.  Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. , 2003, The New England journal of medicine.

[15]  A. Kangarlu,et al.  Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. , 2007, AJNR. American journal of neuroradiology.

[16]  K. Hasan,et al.  Magnetic resonance imaging–based quantitative iron mapping at 7‐Tesla remains to be elusive in multiple sclerosis , 2009, Annals of neurology.

[17]  S. Nelson,et al.  Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron , 2008, Annals of neurology.

[18]  A. Bartoš,et al.  Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis , 2013, Journal of Neuroimmunology.

[19]  L. Kappos,et al.  Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF , 2007, Journal of Neurology.

[20]  J A Frank,et al.  Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. , 2006, AJNR. American journal of neuroradiology.

[21]  R. Leslie,et al.  Principles of Autoantibodies as Disease-specific Markers , 2004, Autoimmunity.

[22]  Chiara Romualdi,et al.  Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. , 2007, Archives of neurology.

[23]  A. Lugaresi,et al.  Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study , 2013, Journal of Neurology.

[24]  F. Mcdowell,et al.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.

[25]  M. Carreras,et al.  A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[26]  G. Giovannoni,et al.  Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis , 2005, Multiple sclerosis.

[27]  W. Brück,et al.  Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis , 2008, Brain : a journal of neurology.

[28]  G. Comi,et al.  Magnetization transfer imaging to monitor the evolution of MS , 2000, Neurology.

[29]  David H. Miller,et al.  Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. , 2004, Brain : a journal of neurology.

[30]  R. Daroff,et al.  Magnetic resonance images on Marburg variant. , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[31]  Lawrence Steinman,et al.  Multiple sclerosis: a two-stage disease , 2001, Nature Immunology.

[32]  R. R. Smith,et al.  MRI in acute disseminated encephalomyelitis , 1994, Neuroradiology.

[33]  R. Kinkel,et al.  Management of multiple sclerosis. , 1997, The New England journal of medicine.

[34]  MRI lesions: a surrogate for relapses in multiple sclerosis? , 2013, The Lancet Neurology.

[35]  D. Li,et al.  Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients , 1989, Annals of neurology.

[36]  F. Bouwman,et al.  Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis , 2009, Neurology.

[37]  Marco Rovaris,et al.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.

[38]  H. Weiner,et al.  Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis , 1994, The Journal of experimental medicine.

[39]  H. Hartung,et al.  Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis , 2005 .

[40]  H. Prince Biomarkers for diagnosing and monitoring autoimmune diseases , 2005, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[41]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[42]  Yoshito Tsushima,et al.  Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis , 2009, BMJ : British Medical Journal.

[43]  R. Bakshi,et al.  Acute hemorrhagic leukoencephalitis vs ADEM: FLAIR MRI and neuropathology findings , 2003, Neurology.

[44]  Michael Wall,et al.  High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. , 2003, Archives of ophthalmology.

[45]  David H. Miller,et al.  Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis , 2002, Annals of neurology.

[46]  B. Trapp,et al.  Multiple sclerosis: an immune or neurodegenerative disorder? , 2008, Annual review of neuroscience.

[47]  David H. Miller,et al.  Lack of association between antimyelin antibodies and progression to multiple sclerosis. , 2007, The New England journal of medicine.

[48]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[49]  D. Martino,et al.  Soluble adhesion molecules in acute disseminated encephalomyelitis. , 2005, Pediatric neurology.

[50]  C. Polman,et al.  Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. , 2004, Archives of neurology.

[51]  R. Bakshi,et al.  Acute disseminated encephalomyelitis in children. , 2002, Pediatrics.

[52]  B. Weinshenker,et al.  Acute Disseminated Encephalomyelitis, Transverse Myelitis, and Neuromyelitis Optica , 2013, Continuum.

[53]  L. Jacobs,et al.  Impact of nuclear magnetic resonance imaging on the assessment of multiple sclerosis patients. , 1986, Seminars in neurology.

[54]  À. Rovira,et al.  Antimyelin antibodies with no progression to multiple sclerosis. , 2007, The New England journal of medicine.

[55]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[56]  B. Scheithauer,et al.  Inflammatory cortical demyelination in early multiple sclerosis. , 2011, The New England journal of medicine.

[57]  B. Weinshenker,et al.  The spectrum of neuromyelitis optica , 2007, The Lancet Neurology.

[58]  J. Lünemann,et al.  Elevated Epstein–Barr virus‐encoded nuclear antigen‐1 immune responses predict conversion to multiple sclerosis , 2010, Annals of neurology.

[59]  D. Goodin,et al.  Incidental MRI anomalies suggestive of multiple sclerosis , 2009, Neurology.

[60]  A. Bartoš,et al.  Serum and cerebrospinal fluid heavy neurofilaments and antibodies against them in early multiple sclerosis , 2013, Journal of Neuroimmunology.

[61]  B E Kendall,et al.  The early risk of multiple sclerosis after optic neuritis. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[62]  J Sastre-Garriga,et al.  New diagnostic criteria for multiple sclerosis , 2003, Neurology.

[63]  À. Rovira,et al.  Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS , 2001, Multiple sclerosis.

[64]  B E Kendall,et al.  The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. , 1987, Brain : a journal of neurology.

[65]  H. Hartung,et al.  Acute disseminated encephalomyelitis: an acute hit against the brain , 2007, Current opinion in neurology.

[66]  A. Thompson,et al.  Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis , 2005, The Lancet Neurology.

[67]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[68]  A. Cross,et al.  Oligoclonal band number as a marker for prognosis in multiple sclerosis. , 2001, Archives of neurology.

[69]  S. Suissa,et al.  Acute disseminated encephalomyelitis cohort study: prognostic factors for relapse. , 2007, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[70]  U. Rot,et al.  Clinical, MRI, CSF and electrophysiological findings in different stages of multiple sclerosis , 2006, Clinical Neurology and Neurosurgery.

[71]  S. Sorbi,et al.  The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis , 2009, Multiple sclerosis.

[72]  M. Filippi,et al.  A 3‐year magnetic resonance imaging study of cortical lesions in relapse‐onset multiple sclerosis , 2009, Annals of neurology.

[73]  V. Torri,et al.  Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests , 1999, Journal of Neurology.

[74]  D. Miller,et al.  The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. , 1993, Brain : a journal of neurology.

[75]  F. Barkhof,et al.  Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b , 2008, Journal of Neurology.

[76]  Bernhard Hemmer,et al.  Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis , 2010, Journal of Neuroimmunology.

[77]  I. Mader,et al.  Acute haemorrhagic encephalomyelitis (AHEM): MRI findings. , 2004, Neuropediatrics.

[78]  J. Aicardi,et al.  Schilder's myelinoclastic diffuse sclerosis. , 1986, Pediatrics.

[79]  J. Oger,et al.  Multiple sclerosis , 1988, Neurology.

[80]  A. Thompson,et al.  The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. , 1998, Brain : a journal of neurology.

[81]  A. Lutterotti,et al.  Smoking is a risk factor for early conversion to clinically definite multiple sclerosis , 2008, Multiple sclerosis.

[82]  Ludwig Kappos,et al.  Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study , 2007, The Lancet.

[83]  M. Freedman,et al.  Anti-α-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event , 2009, Multiple sclerosis.

[84]  F. Barkhof,et al.  Treatment with laquinimod reduces development of active MRI lesions in relapsing MS , 2005, Neurology.

[85]  A. Achiron,et al.  Multiple sclerosis-from probable to definite diagnosis: a 7-year prospective study. , 2000, Archives of neurology.

[86]  E. Frohman,et al.  Multiple sclerosis--the plaque and its pathogenesis. , 2006, The New England journal of medicine.

[87]  À. Rovira,et al.  Do multimodal evoked potentials add information to MRI in clinically isolated syndromes? , 2010, Multiple sclerosis.

[88]  Caterina Mainero,et al.  In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI , 2009, Neurology.

[89]  J. Strominger,et al.  Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein , 1995, Cell.

[90]  R J Albertini,et al.  T cells responsive to myelin basic protein in patients with multiple sclerosis. , 1990, Science.

[91]  M. Ferrari,et al.  Migraine as a risk factor for subclinical brain lesions. , 2004, JAMA.

[92]  B. Weinshenker,et al.  Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. , 2009, Archives of neurology.

[93]  Marco Rovaris,et al.  A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. , 2009, Archives of neurology.

[94]  Gavin Giovannoni,et al.  Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. , 2005, Archives of neurology.

[95]  F. Barkhof,et al.  Does high field MRI allow an earlier diagnosis of multiple sclerosis? , 2008, Journal of Neurology.

[96]  M. Filippi,et al.  Intracortical lesions , 2010, Neurology.

[97]  R. Reynolds,et al.  Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. , 2007, Brain : a journal of neurology.

[98]  G. Comi,et al.  Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. , 1997, Brain : a journal of neurology.

[99]  E. Waubant,et al.  Are initial demyelinating event recovery and time to second event under differential control? , 2006, Neurology.

[100]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[101]  F. Barkhof,et al.  MRI criteria for MS in patients with clinically isolated syndromes , 2010, Neurology.

[102]  Ariel Miller,et al.  Serum anti-Glc(α1,4)Glc(α) antibodies as a biomarker for relapsing–remitting multiple sclerosis , 2006, Journal of the Neurological Sciences.

[103]  Massimo Filippi,et al.  Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management , 2005, The Lancet Neurology.

[104]  J. Prineas,et al.  Multiple sclerosis: Capping of surface immunoglobulin G on macrophages engaged in myelin breakdown , 1981, Annals of neurology.

[105]  Marco Rovaris,et al.  MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study , 2007, The Lancet Neurology.

[106]  J. Masjuán,et al.  Clinically isolated syndromes , 2006, Neurology.

[107]  M. Filippi,et al.  Cortical lesions in multiple sclerosis , 2010, Nature Reviews Neurology.

[108]  David H. Miller,et al.  A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. , 2002, The New England journal of medicine.

[109]  Michael Khalil,et al.  Neurofilaments as biomarkers in multiple sclerosis , 2012, Multiple sclerosis.

[110]  S. Ng,et al.  Acute necrotizing encephalopathy of childhood: correlation of MR findings and clinical outcome. , 2006, AJNR. American journal of neuroradiology.

[111]  E. Mowry,et al.  Clinical predictors of early second event in patients with clinically isolated syndrome , 2009, Journal of Neurology.

[112]  U. Zettl,et al.  Immune-mediated CNS diseases: a review on nosological classification and clinical features. , 2012, Autoimmunity reviews.

[113]  K. Venken,et al.  Memory CD4+CD127high T cells from patients with multiple sclerosis produce IL-17 in response to myelin antigens , 2010, Journal of Neuroimmunology.

[114]  H. Hartung,et al.  The role of B cells and autoantibodies in multiple sclerosis , 2000, Annals of neurology.

[115]  A. Rovira,et al.  Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? , 2008, Neurology.

[116]  B. Harding,et al.  Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. , 2000, Brain : a journal of neurology.

[117]  G. Comi,et al.  Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. , 2000, AJNR. American journal of neuroradiology.

[118]  A. Hofman,et al.  Incidental findings on brain MRI in the general population. , 2007, The New England journal of medicine.

[119]  B. Weinshenker,et al.  Revised diagnostic criteria for neuromyelitis optica , 2006, Neurology.

[120]  A. Thompson,et al.  Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[121]  H. Link,et al.  Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness , 2006, Journal of Neuroimmunology.

[122]  P. Vermersch,et al.  Prospective study of patients presenting with acute partial transverse myelopathy , 2003, Journal of Neurology.

[123]  D. Wingerchuk NEUROMYELITIS OPTICA SPECTRUM DISORDERS , 2010, Continuum.

[124]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[125]  C. Polman,et al.  Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis , 2009, The Lancet Neurology.

[126]  Rosman Np,et al.  ACUTE HEMORRHAGIC LEUKOENCEPHALITIS : RECOVERY AND REVERSAL OF MAGNETIC RESONANCE IMAGING FINDINGS IN A CHILD , 1997 .

[127]  S. Tsuji,et al.  IFNβ-1b may severely exacerbate Japanese opticspinal MS in neuromyelitis optica spectrum: Japanese optic-spinal MS: Is it MS or neuromyelitis optica and does the answer dictate treatment? , 2011, Neurology.

[128]  B. Serafini,et al.  Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis , 2004, Brain pathology.

[129]  T. Scott,et al.  Acute partial transverse myelitis with normal cerebral magnetic resonance imaging: transition rate to clinically definite multiple sclerosis , 2005, Multiple sclerosis.

[130]  C. Wolfson,et al.  Incidence and prevalence of multiple sclerosis in Europe: a systematic review , 2013, BMC Neurology.